NASDAQ$BKYI
Bio-key International Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported an 18% increase in revenue, a reduction in net loss, and an improved cash position.
BIO-key International, Inc. reported an 18% increase in Q3 2024 revenue to $2.1 million, driven by a rise in license revenue. The company also reduced its net loss and improved its cash position.
- Q3 2024 revenues increased by 18% to $2.1 million compared to $1.8 million in Q3 2023, primarily due to a $0.5 million increase in license revenue.
- Gross profit improved to $1.7 million with a 78.3% gross margin in Q3 2024, compared to $0.3 million with an 18.7% gross margin in Q3 2023.
- Operating expenses were trimmed by $46,000 in Q3 2024 compared to Q3 2023.
- Net loss for Q3 2024 was $0.7 million, an improvement from the $1.8 million net loss in Q3 2023.
Headline financials
Revenue & EPS history
Bio-key · Revenue · Quarterly
$2.14M
Forward guidance
BIO-key expects full year 2024 revenues to meet or exceed the $7.75M achieved in 2023, and continues to pursue opportunities to lower overhead and variable costs, as it progresses the business toward positive operating cash flow and profitability in the coming quarters. Additionally, BIO-key continues to seek potential strategic opportunities that can leverage its core strengths and business platform to create value for its shareholders.
Tailwinds
- Full year 2024 revenues are expected to meet or exceed the $7.75M achieved in 2023.
- Pursuing opportunities to lower overhead and variable costs.
- Progressing towards positive operating cash flow and profitability.
- Seeking potential strategic opportunities to leverage core strengths.
- Building a growing base of high-margin, annually recurring revenue streams from software licenses and services.
Headwinds
- Performance is expected to vary on a quarter-to-quarter basis.
- The timing and impact of larger customer orders can affect results.
- BIO-key has a history of losses and limited revenue.
- BIO-key's ability to continue as a going concern is dependent on raising additional capital.
- BIO-key's common stock could be delisted from the Nasdaq Capital Market if they fail to increase their stockholders’ equity to at least $2.5 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-3.5%
Avg return
Earnings day
-5.3%
Avg return
5 days after
-8.9%
Avg return
30 days after
25%
16 / 63 earnings
Positive
+15.9%
Q1 2017
Best reaction
-25.9%
Q3 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.7% | — | — | |
| Q3 2025 | -2.2% | -4.1% | -27.8% | |
| Q1 2025 | -6.0% | -2.5% | -2.5% | |
| Q2 2025 | -1.3% | -3.7% | -4.9% | |
| Q4 2024 | -23.6% | +2.4% | -6.0% | |
| Q3 2024 | -8.7% | -16.5% | -5.8% | |
| Q2 2024 | -12.0% | -12.0% | +8.5% | |
| Q1 2024 | -11.8% | -10.0% | +5.9% | |
| Q4 2025 | -4.1% | -9.5% | -15.0% | |
| Q4 2023 | -4.8% | -13.8% | -19.0% | |
| Q3 2023 | -10.6% | -15.8% | -10.5% | |
| Q2 2023 | -10.0% | -10.0% | -27.1% | |
| Q1 2023 | +5.3% | +21.5% | +13.8% | |
| Q4 2022 | -3.0% | +8.2% | -9.6% | |
| Q3 2022 | -17.4% | -27.1% | -45.1% | |
| Q2 2022 | -17.0% | -22.6% | -27.6% | |
| Q1 2022 | -2.0% | -6.0% | -17.9% | |
| Q4 2021 | -3.2% | -6.0% | -14.0% | |
| Q3 2021 | -8.2% | -10.8% | -27.5% | |
| Q2 2021 | -7.4% | -5.5% | +3.5% | |
| Q1 2021 | +6.1% | +8.4% | +32.3% | |
| Q4 2020 | +2.9% | -0.9% | -2.6% | |
| Q3 2020 | -8.7% | -4.4% | -3.3% | |
| Q2 2020 | +1.1% | -1.4% | -36.5% | |
| Q4 2019 | -24.2% | -20.7% | -9.8% | |
| Q3 2019 | -9.2% | -12.1% | +0.0% | |
| Q2 2019 | +1.8% | -6.8% | -29.5% | |
| Q1 2019 | -6.2% | -16.9% | -13.1% | |
| Q4 2018 | -6.8% | -4.8% | -9.5% | |
| Q3 2018 | +11.1% | +9.3% | +13.9% | |
| Q2 2018 | -2.2% | -2.2% | -10.4% | |
| Q1 2018 | -11.0% | -1.3% | -0.9% | |
| Q4 2017 | -6.5% | +2.0% | +7.6% | |
| Q3 2017 | -10.8% | -6.1% | -29.1% | |
| Q2 2017 | -3.1% | -4.3% | -10.6% | |
| Q1 2017 | +15.9% | +22.0% | +17.5% | |
| Q4 2016 | -7.8% | -5.1% | -14.1% | |
| Q3 2016 | -25.9% | -7.4% | -18.5% | |
| Q2 2016 | +0.0% | -4.2% | +8.3% | |
| Q1 2016 | -5.9% | — | — | |
| Q4 2015 | +0.0% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +5.6% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | +0.0% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | -3.7% | — | — | |
| Q4 2013 | +7.7% | — | — | |
| Q3 2013 | -10.5% | — | — | |
| Q2 2013 | +3.0% | — | — | |
| Q1 2013 | +9.1% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2012 | +14.3% | — | — | |
| Q1 2012 | +14.3% | — | — | |
| Q4 2011 | -9.1% | — | — | |
| Q3 2010 | -15.4% | — | — | |
| Q3 2011 | -15.4% | — | — | |
| Q2 2010 | +9.1% | — | — | |
| Q2 2011 | +9.1% | — | — | |
| Q1 2011 | -6.7% | — | — | |
| Q4 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro